Market Access & HTA Strategy
Evidence-based pricing, payer engagement, and HTA submission support for UK, European, and GCC markets.
Overview
BioNixus supports pharmaceutical companies in navigating the complex market access landscape across EMEA. Our research-driven approach combines physician insights, payer intelligence, and health economics to develop evidence-based strategies that accelerate formulary access and optimize pricing.
Capabilities
HTA submission support for NICE (UK), G-BA/IQWiG (Germany), HAS/CEPS (France)
Gulf health authority submission support (SFDA, DHA, MOHAP)
Pricing and reimbursement strategy development
Payer research and willingness-to-pay studies
Value dossier and economic model development
Cost-effectiveness and budget impact analysis
Formulary and tender strategy for GCC hospital systems
Reimbursement landscape modelling
Market access stakeholder mapping
Health economics and outcomes research (HEOR)
Deliverables
Market access strategy documents
Payer interview reports and insights
Pricing corridor analysis and recommendations
HTA evidence gap analysis
Cost-effectiveness models
Value proposition and messaging frameworks
Geographic Coverage
UK (NICE, NHS England), EU5 (G-BA, HAS, AIFA, AEMPS), GCC (SFDA, DHA, MOH Kuwait, MOH Qatar), and Egypt (EDA).
Discuss Your Market Access Strategy
Tell us about your project and receive a tailored proposal within 24 hours.
Request a Proposal